Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF2O4T)

• Drug Name: (S)-FLURBIPROFEN Drug Info
• Synonyms: 51543-39-6; esflurbiprofen; (S)-(+)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; UNII-J5ZZK9P7MX; (S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; (S)-2-(2-Fluoro-[1,1'-biphenyl]-4-yl)propanoic acid; (2S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; J5ZZK9P7MX; CHEMBL435298; CHEBI:42446; SYTBZMRGLBWNTM-JTQLQIEISA-N; (2S)-2-(3-fluoro-4-phenylphenyl)propanoic acid; BTS-24332; (S)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (S)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic ac

Indication

Disease Entry	ICD 11	Status	REF
Myalgia	FB56.2	Preregistration	[1]
Osteoarthritis	FA00-FA05	Preregistration	[1]
Scapulohumeral periarthritis	FB53	Preregistration	[1]

• Cross-matching ID:
  PubChem CID: 72099
  ChEBI ID: CHEBI:42446
  CAS Number: CAS 51543-39-6
  TTD Drug ID: DMF2O4T

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[4]
Naproxen	DMZ5RGV	Bursitis		Approved	[5]
Mesalazine	DMOL5IU	Diverticulitis		Approved	[6]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[7]
Bromfenac	DMKB79O	Pain	MG30-MG3Z	Approved	[8]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[9]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[10]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[9]
Suprofen	DMKXJZ7	Miosis	LA11.62	Approved	[11]
Gamma-Homolinolenic acid	DMSXKYG	Malnutrition	5B50-5B71	Approved	[12]

Drug(s) Targeting Prostaglandin G/H synthase 2 (COX-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[13]
Naproxen	DMZ5RGV	Bursitis		Approved	[5]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[14]
Indomethacin	DMSC4A7	Bursitis		Approved	[9]
Celecoxib	DM6LOQU	Dysmenorrhea	GA34.3	Approved	[15]
Nabumetone	DMAT2XH	Osteoarthritis	FA00-FA05	Approved	[16]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[17]
Flurbiprofen	DMGN4BY	Osteoarthritis	FA00-FA05	Approved	[18]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[7]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[9]

Drug(s) Targeting Beta-secretase (BACE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
E-2609	DMTNUJ8	Alzheimer disease	8A20	Phase 3	[19]
verubecestat	DM4CGH5	Alzheimer disease	8A20	Phase 3	[20]
Lanabecestat	DMFJLB6	Alzheimer disease	8A20	Phase 3	[21]
AZD3293	DMJQHXD	Alzheimer disease	8A20	Phase 2/3	[22]
JNJ-54861911	DMGPJ5U	Alzheimer disease	8A20	Phase 2/3	[21]
R-flurbiprofen	DMFIVSR	N. A.	N. A.	Phase 2	[2]
LY2886721	DMV14LM	Alzheimer disease	8A20	Phase 2	[23]
LY3202626	DM7IFNB	Alzheimer disease	8A20	Phase 2	[21]
AZD-3839	DM72FOD	Alzheimer disease	8A20	Phase 1	[24]
LY-2811376	DM8LGWR	Alzheimer disease	8A20	Phase 1	[25]

Drug(s) Targeting Presenilin 1 (PSEN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-flurbiprofen	DMFIVSR	N. A.	N. A.	Phase 2	[2]
(5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone	DMREVX9	Discovery agent	N.A.	Investigative	[26]
(5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone	DMHG7MU	Discovery agent	N.A.	Investigative	[26]
Drug 311951	DMXTCJ1	Discovery agent	N.A.	Investigative	[27]
Drug 311383	DM5QUJV	Discovery agent	N.A.	Investigative	[27]
1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one	DMF9X2T	Discovery agent	N.A.	Investigative	[26]
(2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone	DMJE83O	Discovery agent	N.A.	Investigative	[26]
Drug 311952	DM27ILS	Discovery agent	N.A.	Investigative	[27]
Drug 311440	DMOIFBK	Discovery agent	N.A.	Investigative	[27]
1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene	DM13HGN	Discovery agent	N.A.	Investigative	[28]

Drug(s) Targeting Presenilin 2 (PSEN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-flurbiprofen	DMFIVSR	N. A.	N. A.	Phase 2	[2]
(5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone	DMREVX9	Discovery agent	N.A.	Investigative	[26]
(5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone	DMHG7MU	Discovery agent	N.A.	Investigative	[26]
Drug 311951	DMXTCJ1	Discovery agent	N.A.	Investigative	[27]
Drug 311383	DM5QUJV	Discovery agent	N.A.	Investigative	[27]
1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one	DMF9X2T	Discovery agent	N.A.	Investigative	[26]
(2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone	DMJE83O	Discovery agent	N.A.	Investigative	[26]
Drug 311952	DM27ILS	Discovery agent	N.A.	Investigative	[27]
Drug 311440	DMOIFBK	Discovery agent	N.A.	Investigative	[27]
1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene	DM13HGN	Discovery agent	N.A.	Investigative	[28]

Drug(s) Targeting Gamma-secretase (GS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nirogacestat	DMUP5Z0	Desmoid tumour	2F7C	Approved	[29]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[30]
Semagacestat	DML83IW	Parkinson disease	8A00.0	Phase 3	[31]
R-flurbiprofen	DMFIVSR	N. A.	N. A.	Phase 2	[2]
MK-0752	DMLTAES	Alzheimer disease	8A20	Phase 2	[32]
BMS-708163	DM51LTG	Alzheimer disease	8A20	Phase 2	[33]
CHF-5074	DMTE071	Alzheimer disease	8A20	Phase 2	[34]
RO-4929097	DMXA6B3	Breast cancer	2C60-2C65	Phase 2	[35]
AL102	DMCTWIB	Desmoid tumour	2F7C	Phase 2	[36]
SPI-014	DM5IPUS	Alzheimer disease	8A20	Phase 1	[37]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Beta-secretase (BACE)	TT8JRS7	NOUNIPROTAC	Inhibitor	[2]
Gamma-secretase (GS)	TT9W8GU	APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN	Inhibitor	[2]
Presenilin 1 (PSEN1)	TTZ3S8C	PSN1_HUMAN	Inhibitor	[2]
Presenilin 2 (PSEN2)	TTWN3F4	PSN2_HUMAN	Inhibitor	[2]
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[3]
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025057)
• [2] The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
• [3] 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
• [4] The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
• [5] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [6] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [7] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
• [8] Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [11] Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
• [12] Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
• [13] Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
• [14] Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
• [15] Pfizer. Product Development Pipeline. March 31 2009.
• [16] Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
• [17] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [18] Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
• [19] Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014 March; 13(3): 319-329.
• [20] BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
• [21] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [22] AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008.
• [23] Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9.
• [24] Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57.
• [25] Neurodegenerative disease: Inhibiting beta-secretase in humans. Nature Reviews Drug Discovery 11, 21 (January 2012).
• [26] Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
• [27] Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
• [28] Aryl sulfones: a new class of gamma-secretase inhibitors. Bioorg Med Chem Lett. 2005 May 16;15(10):2685-8.
• [29] Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.J Pharmacol Exp Ther.2010 Jul;334(1):269-77.
• [30] Clinical pipeline report, company report or official report of Roche (2009).
• [31] A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50.
• [32] Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52.
• [33] Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69(11):1430-40.
• [34] CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.Br J Pharmacol.2009 Mar;156(6):982-93.
• [35] Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53.
• [36] Clinical pipeline report, company report or official report of Ayala Pharmaceuticals.
• [37] Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:210756.